TORONTO, ONTARIO--(Marketwired - May 1, 2015) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) is pleased to announce that CEO René Goehrum will be making a presentation at the 2015 Bloom Burton & Co. Healthcare Investor Conference at 9:30am (ET), May 5, 2015 at the Sheraton Centre Toronto Hotel, Toronto, Canada. Mr. Goehrum will provide an overview of the Company and its corporate activities.
Mr. Goehrum will be available for 1:1 meetings on the day of his presentation. These meetings can be arranged via the conference organizers http://www.bloomburton.com/conference/.
About BioSyent Inc.
Listed on the Toronto Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth oriented specialty pharmaceutical company which searches the globe to in-license or acquire innovative pharmaceutical products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients and supporting the healthcare professionals that treat them. Once a product of interest has been found, BioSyent then acquires the exclusive rights to the product and manages it through the Canadian governmental regulatory approval process. Once approved, BioSyent markets the product throughout Canada.
At the date of this press release the Company had 13,871,195 shares issued and outstanding.
This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.
The TSX Venture Exchange assumes no responsibility for the accuracy of this release and neither approves nor disapproves of the same.
Contact Information:
Mr. Rene C. Goehrum
President and CEO
(905) 206-0013
investors@biosyent.com
www.biosyent.com